Background Neoadjuvant chemotherapy (NAC) is a promising method of improving the
survival of resectable gastric cancer. Cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) …

Background The prognosis for stage III gastric cancer is unsatisfactory by D2 gastrectomy
and S-1 adjuvant chemotherapy. Both S-1 plus cisplatin (SC) and paclitaxel plus cisplatin …

Background Postoperative docetaxel plus S-1 (DS) chemotherapy is expected to be the
standard therapeutic strategy for pStage III gastric cancer based on the results of the …

Background The prognosis for stage 3 gastric cancer is not satisfactory, even with S-1
adjuvant chemotherapy. A randomized phase II trial was conducted to compare two and four …

Background The prognosis of patients with gastric cancer with bulky node metastasis, linitis
plastica (type 4), or large ulcero-invasive-type tumors (type 3) remains poor. We conducted a …

Objectives A multi‐center phase II study was conducted to evaluate the safety and efficacy of
neoadjuvant chemotherapy (NAC) with S‐1 plus cisplatin for advanced gastric cancer …

Abstract Background Adjuvant CT after D2 gastrectomy is standard therapy for resectable
advanced GC in Asia. We investigated whether added neoadjuvant (NA) CT can further …

Background Standard treatment for highly advanced gastric cancer (AGC) has not been
established yet. Neoadjuvant chemotherapy (NAC) represents a promising approach, which …

4067 Background: The phase 3 PRODIGY study compared neoadjuvant docetaxel,
oxaliplatin and S-1 (DOS) chemotherapy followed by surgery followed by adjuvant S-1 with …

Objectives Exploring the efficacy and safety of perioperative chemotherapy on patients with
AGC at different clinical and pathological stages. Methods A phase III randomized …